LRRK2 G2385R Leucocyte and Urine Biomarker Study

• Conditions: Parkinson Disease

• Registration Number: NCT04436848
• Lead Sponsor: University of Malaya

Brief Summary

Given the emerging evidence on LRRK2-related biomarkers, this project will focus on identifying leucocyte and urine biomarkers that are altered by the LRRK2 G2385R variant, and investigating the effects of LRRK2 kinase inhibitor (MLi-2) on these biomarkers, using immunoblotting and mass spectrometry.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-06
• Study Start: 2020-06-01
• Study First Submitted: 2020-06-15
• Study First Submitted QC: 2020-06-15
• Last Update Submitted: 2020-06-15
• Study First Posted: 2020-06-18
• Last Update Posted: 2020-06-18
• Primary Completion: 2021-12-31
• Study Completion: 2022-06-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Diagnosis of Parkinson's disease assigned by a movement disorder specialist according to clinical diagnostic criteria
• Age above 18 year-old
• Provision of a written informed consent

Exclusion Criteria

• Physical or mental incapacity to complete study protocol

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Identification of monocyte-based biomarkers for LRRK2 G2385R variant	Two years
Identification of urine-based biomarkers for LRRK2 G2385R variant	Two years

Trial Locations

Locations (1)

University of Malaya Medical Centre; 🇲🇾 Kuala Lumpur, Malaysia